Latest Nitriles Stories

The antidepressant citalopram does not appear to reduce the occurrence of repetitive behaviors in children and teens with autism spectrum disorders, according to a report in the June issue of Archives of General Psychiatry, one of the JAMA/Archives journals.Although the U.S. Food and Drug Administration has not approved any drugs to treat the core symptoms of autism and related disorders, medications are increasingly being used in this population, according to background information in the...

Use of Atypicals In Major Depression Treatment Is Growing, According to a New Report from Decision Resources Patient-Flow Forecasts Between Pristiq and Effexor XR Need to Take Into Account Reimbursement Hurdles WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories' Lexapro is no longer the leading first-line agent of choice for the treatment of...

Preliminary results of a new study suggest that pregnant women who are also substance-dependent and smoke cigarettes may significantly benefit from certain antidepressant drugs.In particular, researchers noted that the antidepressant bupropion "“ commonly known by the brand name Wellbutrin "“ helped women to curb their smoking habits."We are encouraged by the findings given that both depression and smoking are highly prevalent in pregnant, substance-dependent patients and are associated...

NEW YORK, March 20, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for Lexapro (escitalopram oxalate) for the acute and maintenance treatment of Major Depressive Disorder (MDD) in adolescents, 12 - 17 years of age. Lexapro is only the second antidepressant to be approved for the treatment of MDD in adolescents, a medical condition that...

NEW YORK, Feb. 26, 2009 /PRNewswire-FirstCall/ --Forest Laboratories, Inc. (NYSE: FRX) today announced that a complaint filed against the Company by the United States was unsealed in Massachusetts federal court alleging violations of the federal False Claims Act arising from Forest's marketing of its antidepressants Lexapro(R) and Celexa(R). The Complaint alleges that Forest personnel improperly promoted Lexapro and Celexa for off-label pediatric use, and that Forest paid kickbacks to...

U.S. authorities accused a New York pharmaceutical company Wednesday of making false claims about two antidepressants it markets for unapproved pediatric use. The civil complaint unsealed in U.S. District Court in Massachusetts, not only alleges Forest Laboratories Inc. marketed Celexa and Lexapro improperly but that it paid kickbacks to doctors to prescribe them. The U.S. attorney's office alleges the company's illegal promotional tactics caused thousands of false and fraudulent claims to...

Pharmaceutical Company Allegedly Marketed Drugs for Unapproved Pediatric Use and Paid Kickbacks WASHINGTON, Feb. 25 /PRNewswire-USNewswire/ -- A Complaint was unsealed today in U.S. District Court in Massachusetts against a New York pharmaceutical company for alleged False Claims Act violations arising from the company's marketing the drugs Celexa and Lexapro for unapproved pediatric use and for paying kickbacks to induce physicians to prescribe the drugs. Acting Assistant Attorney...

U.S. researchers announced on Tuesday that the antidepressant Lexapro seemed to ease anxiety in older adults, but the outcome is "modest" and requires further investigation. Antidepressants like Lexapro, which contains escitalopram, may be used for elder adults with a general kind of anxiety disorder, a situation that can create muscle tension, insomnia and exhaustion.Despite the benefits of escitalopram, the findings are slightly weakened from lack of adherence to the drug by...

OVERLAND PARK, Kan., Dec. 15 /PRNewswire/ -- Dechra Veterinary Products LLC today announces that the company has received FDA approval to market VETORYL(R) Capsules. VETORYL Capsules contain the drug trilostane, which has been demonstrated to be effective in the treatment of Cushing's syndrome in dogs. VETORYL will be indicated for use in pituitary-dependent hyperadrenocorticism, which comprises the majority of cases of Cushing's syndrome in dogs. Additionally, VETORYL has received...

Takeda Pharmaceutical Company, a research-based global pharmaceutical company, has filed a new drug application to the Ministry of Health, Labour and Welfare for Alogliptin for treatment of type 2 diabetes. Alogliptin is a dipeptidyl peptidase-IV inhibitor taken once a day, and was created by Takeda San Diego, Takeda's wholly-owned subsidiary located in San Diego, California. Large-scale clinical studies conducted both in Japan and in the world demonstrated that Alogliptin was effective...